Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

The TP73 complex network: ready for clinical translation in cancer?

Soldevilla B, Millán CS, Bonilla F, Domínguez G.

Genes Chromosomes Cancer. 2013 Nov;52(11):989-1006. doi: 10.1002/gcc.22095. Epub 2013 Aug 1. Review.

PMID:
23913810
2.

Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.

Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C, Moll UM.

Cancer Res. 2004 Apr 1;64(7):2449-60.

3.

DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1.

Domínguez G, García JM, Peña C, Silva J, García V, Martínez L, Maximiano C, Gómez ME, Rivera JA, García-Andrade C, Bonilla F.

J Clin Oncol. 2006 Feb 10;24(5):805-15. Epub 2005 Dec 27.

PMID:
16380414
4.

Regulating p73 isoforms in human tumours.

Coates PJ.

J Pathol. 2006 Dec;210(4):385-9. Review.

PMID:
17044134
5.

The presence of an intronic deletion in p73 and high levels of ZEB1 alter the TAp73/DeltaTAp73 ratio in colorectal carcinomas.

Domínguez G, Peña C, Silva J, García JM, García V, Rodríguez R, Cantos B, Citores MJ, España P, Bonilla F.

J Pathol. 2006 Dec;210(4):390-7.

PMID:
17029218
6.

TP73, an under-appreciated player in non-Hodgkin lymphoma pathogenesis and management.

Hassan HM, Dave BJ, Singh RK.

Curr Mol Med. 2014 May;14(4):432-9. Review.

PMID:
24730526
7.

Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.

Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R.

Clin Cancer Res. 2005 Dec 1;11(23):8372-83.

8.

Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations.

Faridoni-Laurens L, Tourpin S, Alsafadi S, Barrois M, Temam S, Janot F, Koscielny S, Bosq J, Bénard J, Ahomadegbe JC.

Cell Cycle. 2008 Jun 1;7(11):1587-96. Epub 2008 Mar 2.

PMID:
18469517
9.

Overexpressed TP73 induces apoptosis in medulloblastoma.

Castellino RC, De Bortoli M, Lin LL, Skapura DG, Rajan JA, Adesina AM, Perlaky L, Irwin MS, Kim JY.

BMC Cancer. 2007 Jul 12;7:127.

10.

The role of the TP73 gene and its transcripts in neuro-oncology.

Jancalek R.

Br J Neurosurg. 2014 Oct;28(5):598-605. doi: 10.3109/02688697.2014.908162. Epub 2014 Apr 17. Review.

PMID:
24742294
11.

Differential regulation of TP73 isoforms by 1α,25-dihydroxyvitamin D3 and survivin in human colon and breast carcinomas.

Díaz R, González-Sancho JM, Soldevilla B, Silva J, García JM, García V, Peña C, Herrera M, Gómez I, Bonilla F, Domínguez G.

Genes Chromosomes Cancer. 2010 Dec;49(12):1135-42. doi: 10.1002/gcc.20821.

PMID:
20842728
12.

Prognostic impact of ΔTAp73 isoform levels and their target genes in colon cancer patients.

Soldevilla B, Díaz R, Silva J, Campos-Martín Y, Muñoz C, García V, García JM, Peña C, Herrera M, Rodriguez M, Gómez I, Mohamed N, Marques MM, Bonilla F, Domínguez G.

Clin Cancer Res. 2011 Sep 15;17(18):6029-39. doi: 10.1158/1078-0432.CCR-10-2388. Epub 2011 Aug 1.

13.

TP53 family members and human cancers.

Bénard J, Douc-Rasy S, Ahomadegbe JC.

Hum Mutat. 2003 Mar;21(3):182-91. Review.

PMID:
12619104
14.

How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors.

Candi E, Agostini M, Melino G, Bernassola F.

Hum Mutat. 2014 Jun;35(6):702-14. doi: 10.1002/humu.22523. Epub 2014 Mar 7. Review.

PMID:
24488880
15.

The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site.

Orzol P, Holcakova J, Nekulova M, Nenutil R, Vojtesek B, Coates PJ.

Histol Histopathol. 2015 May;30(5):503-21. doi: 10.14670/HH-30.503. Epub 2014 Dec 16. Review.

PMID:
25510918
16.

Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients.

Wager M, Guilhot J, Blanc JL, Ferrand S, Milin S, Bataille B, Lapierre F, Denis S, Chantereau T, Larsen CJ, Karayan-Tapon L.

Br J Cancer. 2006 Oct 23;95(8):1062-9.

17.

Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.

Emmrich S, Wang W, John K, Li W, Pützer BM.

Mol Cancer. 2009 Aug 11;8:61. doi: 10.1186/1476-4598-8-61.

18.

DNp73 a matter of cancer: mechanisms and clinical implications.

Buhlmann S, Pützer BM.

Biochim Biophys Acta. 2008 Apr;1785(2):207-16. doi: 10.1016/j.bbcan.2008.01.002. Epub 2008 Feb 12. Review.

PMID:
18302944
19.

Molecular mechanism of p73-mediated regulation of hepatitis B virus core promoter/enhancer II: implications for hepatocarcinogenesis.

Buhlmann S, Racek T, Schwarz A, Schaefer S, Pützer BM.

J Mol Biol. 2008 Apr 18;378(1):20-30. doi: 10.1016/j.jmb.2008.02.021. Epub 2008 Feb 20.

PMID:
18342333
20.

TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy.

Costanzo A, Pediconi N, Narcisi A, Guerrieri F, Belloni L, Fausti F, Botti E, Levrero M.

FEBS Lett. 2014 Aug 19;588(16):2590-9. doi: 10.1016/j.febslet.2014.06.047. Epub 2014 Jun 28.

Supplemental Content

Support Center